US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

VictoryShares US Discovery Enhanced Volatility Wtd ETF

50.92

+0.10190.20%

Post-market: 50.89-0.0309-0.06%16:05 EDT

Volume:2.74K

Turnover:139.47K

Market Cap:25.46M

PE:- -

High:50.92

Open:50.84

Low:50.84

Close:50.82

Loading ...

Overview Company News Filings

Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases

Spruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

Gain Therapeutics Presents Additional Preclinical Data and Design of Phase 1b Clinical Study of GT-02287 at AD/PD 2025 and Provides Enrollment Update

Cerevance Presents Positive Results from Phase 1 Study of CVN293 at American Academy of Neurology 2025 Annual Meeting

Arvinas Potential Parkinson's Treatment Shows Positive Data In Human Study

Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation

Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease

Vigil Neuroscience Presents Data on its Small Molecule TREM2 Agonist VG-3927 in Two Oral Presentations at AD/PD™ 2025 International Conference

Press Release: Vigil Neuroscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Updates

Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer

Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets

Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights

Voyager Reports Positive Topline Data for Single Ascending Dose (SAD) Trial of Anti-Tau Antibody VY7523 and Initiates Multiple Ascending Dose (MAD) Trial in Alzheimer’s Disease

Victory Portfolios II Announces Liquidation of ETFs

Cognition Therapeutics Publishes Research Supporting the Potential of Zervimesine in Dry AMD

uniQure Announces 2024 Financial Results and Highlights Recent Company Progress

Plus Therapeutics Advances Lead Drug Rhenium (186Re) Obisbemeda for Patients with Leptomeningeal Metastases

Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata

Plus Therapeutics Announces Leadership Appointments for its CNSide Diagnostics Subsidiary

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CSF/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CSF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CSF\",,,,,undefined,":{"symbol":"CSF","market":"US","secType":"STK","nameCN":"VictoryShares US Discovery Enhanced Volatility Wtd ETF","latestPrice":50.9209,"timestamp":1744920000000,"preClose":50.819,"halted":0,"volume":2742,"hourTrading":{"tag":"盘后","latestPrice":50.89,"preClose":50.9209,"latestTime":"16:05 EDT","volume":2,"amount":101.8418,"timestamp":1744920313821},"delay":0,"floatShares":500000,"shares":500000,"eps":0,"marketStatus":"Market Closed","change":0.1019,"latestTime":"04-17 16:00:00 EDT","open":50.84,"high":50.9209,"low":50.84,"amount":139469.3583,"amplitude":0.001592,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":50.819,"sharesOutstanding":500000,"nav":50.919731,"aum":25459850,"bidAskSpread":0.001349,"preHourTrading":{"tag":"盘前","latestPrice":50.819,"preClose":50.819,"latestTime":"08:02 EDT","volume":8,"amount":406.552,"timestamp":1744891358272},"postHourTrading":{"tag":"盘后","latestPrice":50.89,"preClose":50.9209,"latestTime":"16:05 EDT","volume":2,"amount":101.8418,"timestamp":1744920313821},"volumeRatio":0.3635254778799937},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CSF\",,,,,undefined,":{"symbol":"CSF","floatShares":500000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.3635254778799937,"shares":500000,"dividePrice":0.78061,"high":50.9209,"amplitude":0.001592,"preClose":50.819,"low":50.84,"week52Low":47.7503,"pbRate":"--","week52High":60.63,"institutionHeld":0,"latestPrice":50.9209,"eps":0,"divideRate":0.01533,"volume":2742,"delay":0,"ttmEps":0,"open":50.84,"prevYearClose":54.8761,"prevWeekClose":50.7,"prevMonthClose":51.5505,"prevQuarterClose":51.5505,"fiveDayClose":50.55,"twentyDayClose":52.06,"sixtyDayClose":56.7724},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CSF\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2527163224","title":"Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases","url":"https://stock-news.laohu8.com/highlight/detail?id=2527163224","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527163224?lang=en_us&edition=fundamental","pubTime":"2025-04-15 19:30","pubTimestamp":1744716600,"startTime":"0","endTime":"0","summary":"New abstract published ahead of the Nuclear Medicine and Neurooncology Conference shows promise for REYOBIQ. Finally, RNA sequencing of LM cells showed early induction of apoptosis, with an innate immune response followed by an increase in T cells and an adaptive immune response by Day 28. Further details can be found here; the Company will provide additional data and explanation following the meeting.About Leptomeningeal Metastases LM is a rare complication of cancer in which the primary cancer spreads to the cerebrospinal fluid  and leptomeninges surrounding the brain and spinal cord. All malignancies originating from solid tumors, primary brain tumors, or hematological malignancies have this LM complication potential with breast cancer as the most common cancer linked to LM, with 3-5% of breast cancer patients developing LM. Additionally, lung cancer, GI cancers and melanoma can also spread to","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/plus-therapeutics-presents-data-highlighting-113000997.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NCI","BK4202","BK4007","CNS","PSTV","CSF","BK4135","LENZ","BK4139"],"gpt_icon":0},{"id":"2527449455","title":"Spruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2527449455","media":"Business Wire","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527449455?lang=en_us&edition=fundamental","pubTime":"2025-04-15 19:00","pubTimestamp":1744714800,"startTime":"0","endTime":"0","summary":"Biologics License Application  Submission to U.S. FDA for Tralesinidase Alfa Enzyme Replacement Therapy  Anticipated in 1H 2026. SOUTH SAN FRANCISCO, Calif., April 15, 2025----Spruce Biosciences, Inc. , a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the company’s new corporate strategy and acquisition of tralesinidase alfa enzyme replacement therapy  for the treatment of Sanfilippo Syndrome Type B .Seek regulatory approval and maximize the U.S. commercial potential of TA-ERT for the treatment of MPS IIIB. Spruce intends to seek U.S. accelerated approval of TA-ERT for MPS IIIB based on existing non-clinical and clinical data. As a condition of seeking such approval of a BLA from the FDA, Spruce will initiate a confirmatory trial. If the BLA is approved, Spruce intends to build a highly specialized commercial and medical affairs organization to support the com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spruce-biosciences-announces-corporate-strategy-110000733.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4595","BK4139","BK4596","BK4585","SPRB","BK4156","STRK","BK4023","BK4600","BK4516","BK4588","CSF"],"gpt_icon":1},{"id":"2526517485","title":"Gain Therapeutics Presents Additional Preclinical Data and Design of Phase 1b Clinical Study of GT-02287 at AD/PD 2025 and Provides Enrollment Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2526517485","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526517485?lang=en_us&edition=fundamental","pubTime":"2025-04-10 19:00","pubTimestamp":1744282800,"startTime":"0","endTime":"0","summary":"GT-02287 oral presentation demonstrates new evidence of disease-modifying capacity in GBA1 and idiopathic Parkinson’s disease models. Phase 1b study ongoing to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of GT-02287 in people with Parkinson’s disease; biomarker analysis to be conducted in Q2 2025. Summary: In animal models of both GBA1 and idiopathic Parkinson’s disease, GT-02287 is able to rescue motor deficits and prevent the development of deficits in complex behaviors such as nesting. These effects persist even following withdrawal of the compound, suggesting a disease-modifying potential of GT-02287. The new preclinical data that were pres","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gain-therapeutics-presents-additional-preclinical-110000583.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4585","GT","LU1169590202.USD","PD","PK","GANX","BK4023","LENZ","BK4181","BK4218","LU1169589451.USD","CSF","BK4119","BK4139","BK4588"],"gpt_icon":0},{"id":"2525814141","title":"Cerevance Presents Positive Results from Phase 1 Study of CVN293 at American Academy of Neurology 2025 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2525814141","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525814141?lang=en_us&edition=fundamental","pubTime":"2025-04-08 23:00","pubTimestamp":1744124400,"startTime":"0","endTime":"0","summary":"CVN293 was generally well-tolerated in healthy volunteers with evidence of robust brain penetration, supporting utility of KCNK13 inhibitors for neurodegenerative diseases characterized by neuroinflam","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/08/3057821/0/en/Cerevance-Presents-Positive-Results-from-Phase-1-Study-of-CVN293-at-American-Academy-of-Neurology-2025-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AFG","CNS","BK4178","BK4107","BK4117","BK4135","AAN","CSF"],"gpt_icon":0},{"id":"2525329377","title":"Arvinas Potential Parkinson's Treatment Shows Positive Data In Human Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2525329377","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525329377?lang=en_us&edition=fundamental","pubTime":"2025-04-05 03:38","pubTimestamp":1743795511,"startTime":"0","endTime":"0","summary":"Arvinas, Inc. unveiled first-in-human data on Friday for its experimental Parkinson’s disease treatment, ARV-102.Results from the randomized, double-blind, placebo-controlled single ascending dose  cohort of the Phase 1 healthy volunteer trial and initial results from the multiple ascending dose  cohort were shared in a presentation at the 2025 International Conference on Alzheimer’s and Parkinson’s Diseases.The Phase 1 trial included SAD cohorts from 10 mg to 200 mg and MAD cohorts of 10 mg to 80 mg in healthy volunteers.In the trial ARV-102, the company’s investigational PROteolysis TArgeting Chimera  leucine-rich repeat kinase 2  degrader, demonstrated substantial reduction of LRRK2, a multifunctional protein that has been implicated in Parkinson’s disease and progressive supranuclear palsy , in cerebral spinal fluid .Also Read: Arvinas, Pfizer Breast Cancer Drug Fails To Show Progression-Free Survival Benefit In Trial. While LRRK2 is primarily known for its role in Parkinson’s, Arv","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arvinas-potential-parkinsons-treatment-shows-193831011.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ARVN","PSP","BK4007","CSF"],"gpt_icon":0},{"id":"2524085052","title":"Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation","url":"https://stock-news.laohu8.com/highlight/detail?id=2524085052","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524085052?lang=en_us&edition=fundamental","pubTime":"2025-04-04 19:00","pubTimestamp":1743764400,"startTime":"0","endTime":"0","summary":"–Data demonstrate that ARV-102 was well tolerated, orally bioavailable, and brain-penetrant; ARV-102 achieved central and peripheral LRRK2 reduction indicating substantial LRRK2 protein degradation in","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/04/3055854/0/en/Arvinas-Presents-First-in-Human-Data-for-Investigational-Oral-PROTAC-ARV-102-Demonstrating-Blood-Brain-Barrier-Penetration-and-Central-and-Peripheral-LRRK2-Degradation.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","CSF","LU1169589451.USD","PD","LU1169590202.USD","PSP"],"gpt_icon":0},{"id":"2524146431","title":"Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2524146431","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524146431?lang=en_us&edition=fundamental","pubTime":"2025-04-02 19:30","pubTimestamp":1743593400,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., April 02, 2025  -- Biogen Inc.  today announced that the U.S. Food and Drug Administration  has granted Fast Track designation to BIIB080, an investigational antisense oligonucleotide  therapy targeting tau, for the treatment of Alzheimer’s disease. Fast Track designation is intended to facilitate the development and expedite the review of investigational drugs that treat serious conditions and address unmet medical needs.About BIIB080BIIB080 is an investigational antisense oligonucleotide  therapy designed to target microtubule-associated protein tau  mRNA to reduce the production of tau protein. Abnormal accumulation of tau in the brain is a hallmark of Alzheimer’s disease and is associated with neurodegeneration and cognitive decline. BIIB080 is currently being evaluated in a Phase 2 clinical study  in individuals with early Alzheimer’s disease.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biogen-investigational-tau-targeting-therapy-113000529.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B19Z9P08.USD","BK4561","MAPT","IE00BYQQ9H92.USD","LU0109394709.USD","BK4023","BK4588","IE00B5TLWC47.USD","IE00BFXG0V08.USD","LU0234570918.USD","IE00B19Z9Z06.USD","LU0320765992.SGD","BK4585","CSF","BIIB","BK4567","IE00B894F039.SGD","BK4192","BK4200","ASO","FAST","LU0889565916.HKD","BK4139","BK4104","BK4532","BK4533","PET"],"gpt_icon":0},{"id":"2524618914","title":"Vigil Neuroscience Presents Data on its Small Molecule TREM2 Agonist VG-3927 in Two Oral Presentations at AD/PD™ 2025 International Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2524618914","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524618914?lang=en_us&edition=fundamental","pubTime":"2025-04-02 19:00","pubTimestamp":1743591600,"startTime":"0","endTime":"0","summary":"- Preclinical presentation highlights key, modality specific, pharmacological differentiations of VG-3927 -- First presentation of topline clinical data from Phase 1 SAD/MAD trial of VG-3927 for the potential treatment of Alzheimer’s disease  -. WATERTOWN, Mass., April 02, 2025  -- Vigil Neuroscience, Inc. , a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today presented data highlighting its oral small molecule program, including its lead clinical candidate VG-3927, in two oral presentations at the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases being held April 1 – April 5 in Vienna, Austria.Oral presentation by Christian Mirescu, Ph.D., Senior Vice President, Neuroimmunology: Small Molecule TREM2 Agonists as Next-Generation Therapeutics for Alzheimer’s DiseaseDate and Time: Wednesday, April 2, 2025, 3:20 PM – 3:35 PM Session: TREM2, Microglia: From Mechanisms to Potenti","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vigil-neuroscience-presents-data-small-110000638.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1169589451.USD","BK4181","BK4563","PAM","ARIA","BK4213","BK4218","PK","BK4081","VG","CSF","BK4139","BK4023","CET","PD","LU1169590202.USD","VIGL"],"gpt_icon":0},{"id":"2519887161","title":"Press Release: Vigil Neuroscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2519887161","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519887161?lang=en_us&edition=fundamental","pubTime":"2025-03-13 19:00","pubTimestamp":1741863600,"startTime":"0","endTime":"0","summary":"Vigil Neuroscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Updates. -- Announced positive data from Phase 1 clinical trial evaluating VG-3927 for potential treatment of Alzheimer's Disease ; plans to initiate Phase 2 clinical trial in Q3 2025 --. -- On track to report final analysis from IGNITE Phase 2 clinical trial evaluating iluzanebart in ALSP in Q2 2025 --. WATERTOWN, Mass., March 13, 2025  -- Vigil Neuroscience, Inc. , a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided updates on recent progress.Final analysis from IGNITE Phase 2 clinical trial planned for second quarter of 2025:. -- The Company plans to report the final analysis from the IGNITE Phase 2. clinical trial, including all patients at 12 months dosed with either 20. iluzanebart in ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4181","BK4218","VIGL","BK4023","PD","LU1169589451.USD","BK4585","03160","CSF","PK","BK4588","BK4604","BK4099","LU1169590202.USD","BK4213","VG","BK4555","TM"],"gpt_icon":0},{"id":"2518877129","title":"Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2518877129","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518877129?lang=en_us&edition=fundamental","pubTime":"2025-03-12 04:01","pubTimestamp":1741723260,"startTime":"0","endTime":"0","summary":"- Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP study; IND filing anticipated in 2026 - - Anti-tau antibody VY7523 was well","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/11/3040977/36461/en/Voyager-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-and-Operating-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSF","CTA","PET","BK4192"],"gpt_icon":0},{"id":"2517694151","title":"Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2517694151","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517694151?lang=en_us&edition=fundamental","pubTime":"2025-03-06 20:30","pubTimestamp":1741264200,"startTime":"0","endTime":"0","summary":"HOUSTON, March  06, 2025  (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company” or “Plus Therapeutics”), a clinical-stage pharmaceutical company developing targeted radiotherapeuti","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/06/3038083/0/en/Plus-Therapeutics-Granted-U-S-FDA-Orphan-Drug-Designation-for-Rhenium-186Re-Obisbemeda-for-the-Treatment-of-Leptomeningeal-Metastases-in-Patients-with-Lung-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCI","ODD","BK4183","CSF","BK4139","LENZ","BK4202"],"gpt_icon":0},{"id":"2517197846","title":"Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2517197846","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517197846?lang=en_us&edition=fundamental","pubTime":"2025-03-06 07:00","pubTimestamp":1741215600,"startTime":"0","endTime":"0","summary":"SAN FRANCISCO, March 5, 2025 /PRNewswire/ -- Nektar Therapeutics  will announce its financial results for the fourth quarter and year-ended December 31, 2024 on Wednesday, March 12, 2025, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.To access the conference call, please pre-register atNektar Earnings Call Registration. All registrants will receive dial-in information and a PIN allowing them to access the live call.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/nektar-announce-financial-results-fourth-230000226.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nektar-announce-financial-results-fourth-230000226.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","CSF","NKTR"],"gpt_icon":0},{"id":"2516620257","title":"Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2516620257","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516620257?lang=en_us&edition=fundamental","pubTime":"2025-03-04 20:00","pubTimestamp":1741089600,"startTime":"0","endTime":"0","summary":"Interim data from Dose 1 PBFT02 demonstrated durable, elevated CSF PGRN and early evidence of reduction in plasma NfL levels, a disease progression biomarker, as compared to published natural history. Enrolled first FTD-GRN patient to be treated with Dose 2 PBFT02, 50% lower than Dose 1. Expect to report 12-month data from Dose 1 and interim safety and biomarker data from Dose 2 in 2H 2025; plan to seek regulatory feedback on FTD-GRN pivotal trial design in 1H 2026. Enrolled first FTD-GRN patient to receive Dose 2 PBFT02: Given the robust CSF PGRN levels achieved at Dose 1 and to aid future discussions with health authorities regarding a registrational study design, the company introduced a lower dose level, Dose 2, which is fifty percent of Dose 1. Dose 2 is expected to be administered to the three remaining FTD-GRN patients in Cohort 2 of the upliFT-D study. The first of these three patients has been enrolled, and multiple patient","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/passage-bio-reports-fourth-quarter-120000494.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GRN","CSF","BK4139","PASG"],"gpt_icon":0},{"id":"2516877576","title":"Voyager Reports Positive Topline Data for Single Ascending Dose (SAD) Trial of Anti-Tau Antibody VY7523 and Initiates Multiple Ascending Dose (MAD) Trial in Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2516877576","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516877576?lang=en_us&edition=fundamental","pubTime":"2025-03-03 20:00","pubTimestamp":1741003200,"startTime":"0","endTime":"0","summary":"- Topline SAD data from healthy volunteers demonstrate safety, tolerability, and dose-proportional pharmacokinetics, supporting potentially best-in-class profile - - MAD study initiated in patients wi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/03/3035441/36461/en/Voyager-Reports-Positive-Topline-Data-for-Single-Ascending-Dose-SAD-Trial-of-Anti-Tau-Antibody-VY7523-and-Initiates-Multiple-Ascending-Dose-MAD-Trial-in-Alzheimer-s-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PK","BK4192","BK4218","BK4181","CSF","PET"],"gpt_icon":0},{"id":"2516043313","title":"Victory Portfolios II Announces Liquidation of ETFs","url":"https://stock-news.laohu8.com/highlight/detail?id=2516043313","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516043313?lang=en_us&edition=fundamental","pubTime":"2025-03-01 05:20","pubTimestamp":1740777600,"startTime":"0","endTime":"0","summary":"SAN ANTONIO, February 28, 2025----Victory Portfolios II today announced plans to liquidate the VictoryShares US Discovery Enhanced Volatility Wtd ETF , VictoryShares US Small Cap Volatility Wtd ETF , and VictoryShares THB Mid Cap ETF  .After the close of business on April 22, 2025, the Funds will no longer accept purchase orders for Creation Units. Shareholders of the Funds may sell their holdings on the Nasdaq Stock Market prior to the close of trading on April 23, 2025, and customary brokerage charges may apply to these transactions. The Funds will cease trading at the end of the trading day on April 23, 2025. It is anticipated that the Funds will liquidate on or about April 29, 2025. Any person holding shares of the Funds as of the liquidation date will receive a cash distribution equal to the net asset value of their shares as of that date.Victory Capital Management Inc. , the adviser to the VictoryShares ETFs, will bear all fees and expenses that may be incurred in connection with","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/victory-portfolios-ii-announces-liquidation-212000839.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4135","CSA","CSF","FDN","LU0149725797.USD","VCTR","MDCP","BK4585","IE00BHPRN162.USD","BK4588","BK4550"],"gpt_icon":0},{"id":"2514809905","title":"Cognition Therapeutics Publishes Research Supporting the Potential of Zervimesine in Dry AMD","url":"https://stock-news.laohu8.com/highlight/detail?id=2514809905","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514809905?lang=en_us&edition=fundamental","pubTime":"2025-02-27 20:30","pubTimestamp":1740659400,"startTime":"0","endTime":"0","summary":"Collaborators at the University of Southampton, UK and Cognition Scientists Show Rescue of Function in a Cell Model of Dry AMDPURCHASE, N.Y., Feb.  27, 2025  (GLOBE NEWSWIRE) -- Cognition Therapeutics","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/27/3033753/0/en/Cognition-Therapeutics-Publishes-Research-Supporting-the-Potential-of-Zervimesine-in-Dry-AMD.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0345774391.USD","IE00BMPRXN33.USD","BK4532","LU1951198990.SGD","LU1880398471.USD","LU2360106780.USD","BK4139","LU2250418816.HKD","LU0823434740.USD","LU1316542783.SGD","LENZ","LU0198837287.USD","LU0127658192.USD","LU0823434583.USD","LU1989764664.SGD","BK4141","IE00BMPRXR70.SGD","CSF","LU0240877869.USD","LU0345774631.USD","BK4007","LU2054465674.USD","LU0240878834.USD","LU1803068979.SGD","DLB","BK4534","BK4585","LU0719512351.SGD","LU1951200564.SGD","BK4554","LU1988902786.USD","LU0081259029.USD","LU0642271901.SGD","BK4529","CGTX","LU2458330243.SGD","LU1880398554.USD","LU1852331112.SGD","LU0082616367.USD","LU2458330169.SGD","LU1242518931.SGD","LU0979878070.USD","LU1303367103.USD","BK4543","LU1064131342.USD","IE0004445239.USD","LU2098885051.SGD","LU2264538146.SGD","GFS"],"gpt_icon":1},{"id":"2514580590","title":"uniQure Announces 2024 Financial Results and  Highlights Recent Company Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2514580590","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514580590?lang=en_us&edition=fundamental","pubTime":"2025-02-27 20:05","pubTimestamp":1740657900,"startTime":"0","endTime":"0","summary":"~ Announced alignment with the U.S. Food and Drug Administration  on key elements of the Accelerated Approval pathway for AMT-130 in Huntington’s disease; Initiated preparations for a potential Biologics License Application  submission ~~ Completed patient enrollment in the third cohort of the Phase I/II study of AMT-130 ~~ Initiated dosing of the Phase I/II study of AMT-260 in mesial temporal lobe epilepsy ; Implementing protocol changes to expand study inclusion criteria ~~ Completed enrollment of the first cohorts in the Phase I/II studies of AMT-191 in Fabry disease and AMT-162 in SOD1-ALS; Received favorable recommendations from the respective Independent Data Monitoring Committees  to proceed with dosing the second cohorts ~LEXINGTON, Mass. and AMSTERDAM, Feb. 27, 2025  -- uniQure N.V. , a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the fourth quarter and full year of 2024 and hig","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/uniqure-announces-2024-financial-results-120500503.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CMC","LU0170899867.USD","LU1363072403.SGD","LU0971096721.USD","BK4006","LU0267386448.USD","BK4139","IE00BZ1G4Q59.USD","LU0149725797.USD","BK4097","IE00BHPRN162.USD","LU2065732104.USD","PRGS","IE00BKVL7J92.USD","IE00B1BXHZ80.USD","CSF","QURE","LU0882574139.USD"],"gpt_icon":0},{"id":"2514619834","title":"Plus Therapeutics Advances Lead Drug Rhenium (186Re) Obisbemeda for Patients with Leptomeningeal Metastases","url":"https://stock-news.laohu8.com/highlight/detail?id=2514619834","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514619834?lang=en_us&edition=fundamental","pubTime":"2025-02-26 20:30","pubTimestamp":1740573000,"startTime":"0","endTime":"0","summary":"ReSPECT- LM Phase 1 single dose is now complete, and the recommended Phase 2 dose (RP2D) for single administration therapy has been determinedAUSTIN, Texas, Feb.  26, 2025  (GLOBE NEWSWIRE) -- Plus Th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/26/3032822/0/en/Plus-Therapeutics-Advances-Lead-Drug-Rhenium-186Re-Obisbemeda-for-Patients-with-Leptomeningeal-Metastases.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4135","CSF","BK4139","CNS"],"gpt_icon":0},{"id":"2514180839","title":"Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata","url":"https://stock-news.laohu8.com/highlight/detail?id=2514180839","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514180839?lang=en_us&edition=fundamental","pubTime":"2025-02-26 20:00","pubTimestamp":1740571200,"startTime":"0","endTime":"0","summary":"SAN FRANCISCO, Feb. 26, 2025 /PRNewswire/ -- Nektar Therapeutics  today announced the company has completed target enrollment in its REZOLVE-AA Phase 2b study of rezpegaldesleukin in patients with severe-to-very-severe alopecia areata.The REZOLVE-AA  study enrolled patients with severe-to-very-severe alopecia areata who have not received a JAK inhibitor or other biologic. Patients were randomized across two different dose regimens of rezpegaldesleukin or placebo. The primary efficacy endpoint will evaluate mean percent change in the Severity of Alopecia Tool  score at the end of the 36-week induction period. Secondary endpoints include proportion of participants with greater than or equal to 50% reduction in SALT score at week 36 and other assessed timepoints, mean percent improvement in SALT score at other assessed timepoints, and proportion of patients achieving SALT-20 .Enrollment criteria in the study included a diagnosis of severe-to-very-severe alopecia areata  as measured using ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/nektar-therapeutics-announces-completion-target-120000330.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nektar-therapeutics-announces-completion-target-120000330.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4585","NKTR","AA","CSF","BK4588","BK4153"],"gpt_icon":0},{"id":"2513769723","title":"Plus Therapeutics Announces Leadership Appointments for its CNSide Diagnostics Subsidiary","url":"https://stock-news.laohu8.com/highlight/detail?id=2513769723","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513769723?lang=en_us&edition=fundamental","pubTime":"2025-02-24 20:30","pubTimestamp":1740400200,"startTime":"0","endTime":"0","summary":"Russell Bradley Named President & General Manager of CNSide Dr. Marc Hedrick, Rick Hawkins, and Russell Bradley Join CNSide Board of Directors Dr. Jonathan Stein Appointed CNSide Medical Director  AUS","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/24/3031047/0/en/Plus-Therapeutics-Announces-Leadership-Appointments-for-its-CNSide-Diagnostics-Subsidiary.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","BK4179","LENZ","BK4139","CNS","NGS","CSF"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":68,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CSF\",params:#limit:5,,,undefined,":[{"date":"2025-04-10","symbol":"CSF","amount":0.053873,"announcedDate":"2025-04-09","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-10","defaultRemindTime":1744291800000,"name":"VictoryShares US Discovery Enhanced Volatility Wtd ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-11","payableDate":"2025-04-10","currency":"USD","dateTimestamp":1744257600000,"payDate":"2025-04-11"},{"date":"2025-03-10","symbol":"CSF","amount":0.09736,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-10","defaultRemindTime":1741613400000,"name":"VictoryShares US Discovery Enhanced Volatility Wtd ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-11","payableDate":"2025-03-10","currency":"USD","dateTimestamp":1741579200000,"payDate":"2025-03-11"},{"date":"2024-12-12","symbol":"CSF","amount":0.194215,"announcedDate":"2024-12-11","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-12","defaultRemindTime":1734013800000,"name":"VictoryShares US Discovery Enhanced Volatility Wtd ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-13","payableDate":"2024-12-12","currency":"USD","dateTimestamp":1733979600000,"payDate":"2024-12-13"},{"date":"2024-11-07","symbol":"CSF","amount":0.016451,"announcedDate":"2024-11-06","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-11-07","defaultRemindTime":1730989800000,"name":"VictoryShares US Discovery Enhanced Volatility Wtd ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-11-08","payableDate":"2024-11-07","currency":"USD","dateTimestamp":1730955600000,"payDate":"2024-11-08"},{"date":"2024-10-08","symbol":"CSF","amount":0.052247,"announcedDate":"2024-10-07","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-10-08","defaultRemindTime":1728394200000,"name":"VictoryShares US Discovery Enhanced Volatility Wtd ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-10-09","payableDate":"2024-10-08","currency":"USD","dateTimestamp":1728360000000,"payDate":"2024-10-09"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CSF\",market:\"US\",,,undefined,":[{"executeDate":"2015-06-16","recordDate":"2015-06-18","paymentDate":"2015-06-19","value":0.0849404,"currency":"USD"},{"executeDate":"2015-09-22","recordDate":"2015-09-24","paymentDate":"2015-09-25","value":0.0863264,"currency":"USD"},{"executeDate":"2015-12-28","recordDate":"2015-12-30","paymentDate":"2015-12-31","value":0.1258576,"currency":"USD"},{"executeDate":"2016-03-08","recordDate":"2016-03-10","paymentDate":"2016-03-11","value":0.0228347,"currency":"USD"},{"executeDate":"2016-06-14","recordDate":"2016-06-16","paymentDate":"2016-06-17","value":0.0798989,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CSF\",market:\"US\",delay:false,,,undefined,":{}}}